Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
20 slides from Mayne Pharma's conference presentation, Jan 11, 2024
Slide 1: ASX Announcement: Mayne Pharma presentation at J.P. Morgan Healthcare Conference
ASX Announcement MAYNE PHARMA PRESENTATION AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE 11 January 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O’Brien, Chief Executive Officer of Mayne Pharma, will present at the 42nd Annual J.P. Morgan
Slide 2: Mayne Pharma Group Limited - J.P. Morgan Healthcare Conference
For personal use only Mayne Pharma Group Limited J.P. Morgan Healthcare Conference Shawn Patrick O’Brien January 11, 2024 MYX.ASX
Slide 3: Disclaimer
Disclaimer The information provided is general in nature and is in summary form only. It is not complete and should be read in conjunction with the company’s audited Financial Statements and market disclosures. This material is not intended to be relied upon as advice to investors or potential inves
Slide 4: Agenda
Agenda For personal use only FY 2023 Review – Transformed To Optimize For Profitable Growth Financial Update – Strong Progress Against Our Goals Dermatology – Access Focus Driving Patient Adherence – Attracting High Quality Partners Women’s Health – Portfolio Delivering Solid Financial Results – Sig
Slide 5: Mayne Pharma months ago
Mayne Pharma 18 months ago •US CDMO business – ~21% FY22 revenues, significant profit For personal use only Majority of revenues contribution, but capital intense under significant pressure + requiring •US RGx business – ~ 36% of FY22 revenues – declining business, large capital outlay long cash con
Slide 6: FY23 Review – Transforming and Optimizing for Growth
FY23 Review – Transforming and Optimizing for Growth For personal use only REFOCUSED ON CORE BUSINESS • Sold US CDMO & US Retail Generics - combined sale price US$565m GREW ALL THREE SEGMENTS • Expanded US Women’s Health portfolio via US$140m exclusive license to commercialize 3 on- • BPD/Women’s He
Slide 7: Strong start to FY24: YTD through Oct 24
Strong start to FY24: YTD through Oct24 - 4 month comparisons Update1 GROUP in A$ m Jul-Oct FY23 Mar-Jun FY23 Jul-Oct FY24 Total Net Sales 33.0 97.8 124.8 For personal use only Total Gross Margin 13.5 47.8 71.7 Total Gross Margin % of Net Sales 41% 49% 57% Direct OPEX 38.6 43.1 45.3 Indirect OPEX 22
Slide 8: Dermatology
For personal use only Dermatology
Slide 9: Dermatology Portfolio Overview
Dermatology Portfolio Overview Building market leadership and scale ● Six proprietary brands and 20+ generic dermatologics For personal use only ● Recent acquisition of RHOFADE®, an FDA-approved topical cream used to treat rosacea (launched 2 Oct 2023) ● Mayne Pharma portfolio can fill 1 in 3 US Der
Slide 10: Dermatology YTD October FY24 results
Dermatology YTD October FY24 results1 FY24 Dermatology ● YTD-FY24 Net Sales +640% vs PCP, +55.5% vs prior 4-month period For personal use only Outlook ● YTD-FY24 Gross Margin +999+% vs PCP, +174% vs prior 4-month period ● Net revenues growing steadily, benefitting from improved GTN and NPLs (DORYX®
Slide 11: Disintermediation Strategy
Disintermediation Strategy Mayne Pharma’s unique platform spans the entire value chain, allowing for the ability to create a comprehensive, frictionless, transparent, and cost-effective experience For personal use only Why Dermatology? Why Mayne Pharma? 130 territory representatives ✓ There is great
Slide 12: Disintermediation Strategy - continued
Disintermediation Strategy - continued Mayne Pharma generates gross-to-net savings via disintermediation and utilizes those savings to lower patient out-of-pocket costs to increase adherence, improve patient and provider satisfaction driving product growth. For personal use only Weekly TRx Volume1 M
Slide 13: Women's Health
For personal use only Women’s Health
Slide 14: Women's Health Portfolio
Women’s Health Portfolio Leader in US Women’s Health For personal use only ● A leading position in strong and growing market with four novel women’s healthcare products1 ● Licensing rights acquisition added a complementary portfolio of stable products with long patent lives to the Company’s flagsh
Slide 15: Women's Health YTD October FY24 results
Women’s Health YTD October FY24 results1 ● YTD-FY24 net sales +45.3% for BPD on prior 4-month period FY24 Women’s Health ● Segment performance reflects growth in expansion portfolio as well For personal use only Outlook as improved performance of NEXTSTELLIS® following access improvements (co-pay) a
Slide 16: NEXTSTELLIS Growth continues
NEXTSTELLIS® Growth continues NEXTSTELLIS Product Overview • First and only oral contraceptive with a native, selective For personal use only estrogen, estetrol (E4). Paired with drospirenone. • E4 has selective actions in tissues • Supports health of key tissues: uterus, vagina, bone, and vasculatu
Slide 17: Licensed Portfolio Delivering Financial Results and Significant Growth Potential
Licensed Portfolio Delivering Financial Results and Significant Growth Potential Imvexxy® Product Overview Bijuva® Product Overview • For personal use only Bio-identical estradiol, two doses available (4 mcg, 10 mcg) • Only FDA-approved combination of bio-identical estradiol and • Lowest vaginal est
Slide 18: Mayne Pharma Outlook
Mayne Pharma Outlook Mayne Pharma is focused on becoming the market leader in Dermatology and Women’s Health in the US market Upcoming Launches Future Portfolio Expansion For personal use only ✓ Dermatology ✓ Innovative Dermatology • Soolantra® AG, Jan 2024 • Recent partnership with MC2 (WYNZORA®) p
Slide 19: Strategy for 2024 Growth
Strategy for 2024 Growth Continuing positive momentum into FY24 – solid Q1 momentum continuing into Q2 and beyond For personal use only Women’s Health Dermatology International ✓ Deliver positive contribution margins in all three segments • Pursue targeted • Complete integration of • Positive profit
Slide 20: Q&A
Q&A For personal use only SHAWN PATRICK O’BRIEN CEO AARON GRAY CFO DANIEL MOORE EVP, Commercial You deserve tomorrow. MYX.ASX 19
Mayne Pharma Group — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix